Achieve Life Sciences, Inc. (ACHV)
NASDAQ: ACHV · Real-Time Price · USD
2.650
+0.170 (6.85%)
May 13, 2025, 4:00 PM - Market closed
Company Description
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction.
The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc., which is headquartered in Vancouver, Canada.
Achieve Life Sciences, Inc.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Richard A. Stewart |
Contact Details
Address: 1040 West Georgia Street, Suite 1030 Vancouver, BC V6E 4H1 Canada | |
| Phone | 604 210 2217 |
| Website | achievelifesciences.com |
Stock Details
| Ticker Symbol | ACHV |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000949858 |
| CUSIP Number | 004468203 |
| ISIN Number | US0044685008 |
| Employer ID | 95-4343413 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Richard A. B. Stewart | Chief Executive Officer and Executive Director |
| Thomas B. King M.B.A. | Interim Executive Chairman |
| Dr. Cindy Jacobs M.D., Ph.D. | President, Chief Medical Officer and Director |
| Mark K. Oki CPA | Chief Financial Officer |
| Jerry Wan | Vice President of Finance and Principal Accounting Officer |
| Dr. Anthony Clarke Ph.D. | Chief Scientific Officer |
| Jaime Xinos | Chief Commercial Officer |
| Dr. Mark L. Rubinstein | Head of Medical Affairs |
| Craig Donnelly | Executive Vice President of CMC and Regulatory CMC |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| May 9, 2025 | SCHEDULE 13G/A | Filing |
| Apr 30, 2025 | SCHEDULE 13G/A | Filing |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 11, 2025 | 10-K | Annual Report |
| Mar 11, 2025 | 8-K | Current Report |
| Feb 10, 2025 | 8-K | Current Report |
| Jan 10, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |